All posts by imreal

OHM Fitness Is Slated To Open 20 Locations In North Carolina


News Image

“We are not newcomers to strength training so it was mind-blowing that we would have the same feeling after a 25-minute low-impact workout with the OHM EMPower suit, that we typically have after a long gym session with heavy weights.”

OHM Fitness will open 20 EMS fitness studios across North Carolina through its newest franchise partners over the next few years.

Luis and Liz Arcos recently secured the area representative rights to North Carolina and plan to open 20 locations across the state. The couple is already searching for retail spaces starting in Raleigh, around 2,000 square feet in grocery-anchored centers. Liz is a commercial broker with Phoenix Commercial Properties, so her experience will be helpful as they plan to open at least one to two locations this year.

OHM Fitness offers a high-tech, high-energy EMS fitness experience that packs the benefits of an intense two-hour workout into a low-impact, 25-minute session. The first studio opened in the company’s headquarters of Scottsdale in August of 2022 and since then, the company has sold the rights to nine territories totaling more than 150 future studios. Territories in development now include Arizona, San Diego, South Florida, New Jersey, Washington D.C, Colorado, Kansas, Missouri and now, North Carolina.

The Arcos have extensive experience in franchising. They were the first franchisee for European Wax Center after meeting co-founder Joshua Coba at a franchise expo. The couple owned a number of European Wax Center locations in North Carolina and sold the business six years ago. Coba reached out to the couple about the new concept after joining OHM Fitness as an area representative for South Florida and they were instantly intrigued. They flew to Scottsdale to experience the studio and to reunite with OHM co-founder and CEO Doug Payne, whom they knew from European Wax Center. After experiencing an OHM Fitness workout, the couple was instantly sold and knew this was something they had to get in on.

“The atmosphere of group training at OHM Fitness is unmatched! The trainer’s energy and encouragement coupled with the studio atmosphere keeps you motivated and wanting to come back,” said Liz Arcos. “We are not newcomers to strength training so it was mind-blowing that we would have the same feeling after a 25-minute low-impact workout with the OHM EMPower suit, that we typically have after a long gym session with heavy weights. We are confident this is going to take off in a big way in North Carolina.”

The duo is planning on opening at least three locations themselves and will award the other licenses to qualified franchisees.

“At OHM Fitness, the EMPower Suit has the ability to produce impressive results with a desirably low rate of wear and tear on your joints, ligaments, and muscles,” said co-founder Doug Payne. “While the body’s central nervous system can only send frequency impulses that control up to 50% of your muscle fibers during an exercise, the EMS technology within the wireless OHM EMPower Suit activates 95% of the muscle. We are revolutionizing the fitness industry with this wireless technology.”

OHM Fitness is a special first-to-market franchise opportunity for entrepreneurs and experienced franchise industry professionals who are eager to capture their share in the $96 billion dollar fitness industry. The initial franchise fee is $39,000 and the total estimated initial investment ranges from $337,500 to $612,700. For more information about franchise opportunities available in your area, please visit http://www.OHMfitness.com or email Franchising@OHMfitness.com.

About OHM Fitness

OHM Fitness is one of the first franchises to deliver small group workouts using highly-effective electrical muscle stimulation (EMS) through the use of wearable technology through its OHM EMPower Suit. This high-tech fitness experience packs the benefits of an intense two-hour workout into a low-impact, 25-minute session with a low rate of wear and tear on the joints, ligaments, and muscles, in comparison to other HiiT workouts. Founded in Scottsdale, Ariz., OHM Fitness currently offers area developer and franchisee opportunities to qualifying entrepreneurs. For more information, please visit http://www.OHMfitness.com or email franchising@OHMFitness.com.

Share article on social media or email:

Sorcero Partners with Google Cloud to Provide AI-Powered Medical Analytics for Life Sciences


“With Sorcero’s platform, customers can rapidly advance the state of medical analytics and accelerate decision-making to improve patient outcomes.” – Riju Khetarpal, Director, Healthcare and Life Sciences ISV Partnerships, Google Cloud

Sorcero, the leading medical analytics platform, today announced it has partnered with Google Cloud. Utilizing Google Cloud’s technologies, Sorcero’s platform will now deliver advanced analytics and generative AI solutions that utilize Google Cloud’s BigQuery and Vertex AI to fine-tune AI models for biomedical labeling, theme detection, and classification.. The collaboration with Google Cloud enables Sorcero to deliver the complete command center and scientific data warehouse to analyze and generate medical content for the life sciences.

Every day, scientific and medical discovery rapidly advances.

Thousands of new biomedical articles are published in peer-reviewed journals. Promising new treatment methods are surfaced in discussions between medical teams and healthcare practitioners. Clinical trials and disease management guidance are shared on social media by patients and advocacy groups. Innovative solutions to unmet needs in healthcare treatment, access, and equity are championed by medical advisory panels. Life Science companies face the enormous challenge of staying informed, sifting through mountains of scientific content to derive medical insights and pinpoint appropriate evidence to share, and tracking the impact of clinical decisions on patient outcomes.

Sorcero’s medical analytics platform, with the addition of Google Cloud’s technology, is purpose-built to address biomedical content challenges. Sorcero’s platform and deep AI technology eliminates data silos, delivering medical analytics and insights faster for data-driven decision-making. Sorcero’s medical Language Intelligence (LI) powered applications take full advantage of the security, scale, and computational power of Google Cloud.

“Life sciences organizations have an incredible opportunity for digital transformation by realizing new insights from available data. They are increasing investments in data platforms that synthesize, and analyze large volumes of disparate data to inform clinical decisions,” said Riju Khetarpal, Director, Healthcare and Life Sciences ISV Partnerships, Google Cloud. “With Sorcero’s platform, customers can rapidly advance the state of medical analytics and accelerate decision-making to improve patient outcomes.”

Sorcero’s platform helps life science companies gather evidence to transform clinical treatment, discover unmet patient needs and under-served populations, detect safety issues, generate medical publications and information, and improve patient outcomes faster than ever before.

Share article on social media or email:

Fable achieves ISO 27001:2013 information security certification


Fable logo above the ISO 27001 certified logo by Schellman

Fable has a deep commitment to serving our stakeholders with a high degree of privacy, reliability, and fairness.

Fable is pleased to announce that the organization is now ISO/IEC 27001:2013 certified. This is the latest addition to the company’s security certifications, having already achieved SOC 2 ® Type 2 certifications for both of their products, Fable Engage and Fable Upskill.

“A mature security stature is important to our customers and our community alike,” said Abid Virani, COO at Fable. “This certification is reflective of not only product security, but that of Fable’s entire organization. We have a deep commitment to serving our stakeholders with a high degree of privacy, reliability, and fairness.”

Achieving ISO 27001:2013 is a milestone for the enterprise SaaS company, attesting to the comprehensive security management standards that specify a set of best practices and controls. Fable has been examined for its information security risks, designated a set of security controls to mitigate these identified risks, adopted a management process that reviews these controls, and finally had the audit conducted by an external party (the audit firm Schellman) that tested for conformity and issued the certification.

Schellman, an independent third-party auditor, found Fable to have the needed technical controls in place and formalized IT Security policies, procedures, security measures, and countermeasures to protect it from unauthorized access or compromise.

“Fable connects a talented community of people with disabilities with the world’s largest enterprises,” said Alwar Pillai, CEO at Fable. “Trust is essential, and we will continue to invest in security as we serve a growing and global clientele.”

About Fable

Fable is the leading digital accessibility platform powered by people with disabilities. Fable helps enterprises build accessible user experiences by engaging people with disabilities throughout the product development cycle – from custom accessibility training to research and testing. Organizations work with Fable to make products more accessible for over the 1 billion people who live with disabilities, and in turn, make products more usable for everyone. For more information, visit: http://www.makeitfable.com.

Media contact:

Ashley Hargreaves

604 323-3347

press@makeitfable.com

Share article on social media or email:

Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts


News Image

Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates targeting highly prevalent skin conditions, today announced that it has commenced enrollment in a Phase 2, 150-person, randomized, double-blind, placebo-controlled clinical trial assessing the safety and efficacy of VDMN in Verruca Vulgaris (common warts).

VDMN is an investigational, proprietary, dissolvable microarray patch technology that administers immunotherapy within the superficial aspect of the skin. It is anticipated that this first-in-category technology will provide an “injection-free” immunotherapy treatment for common warts without creating the degree of pain, “needle-phobia,” and anxiety associated with traditional injections. VDMN has the potential to become a preferred treatment approach for children and young adults where aversion to painful procedures involving needles or freezing with liquid nitrogen and common wart prevalence are all at their highest.

“Common warts, which impact approximately 19 million people in the U.S. alone, are one of the most frequent reasons Americans seek treatment for skin disease,” said Reid Waldman, M.D., CEO at Veradermics. “Despite their high prevalence, there are no FDA approved prescription treatments for common warts. VDMN has the potential to satisfy patient and dermatologist hopes for a convenient, patient-friendly, and effective treatment. The start of our Phase 2 program for VDMN in common warts is a pivotal milestone for Veradermics as the company advances the first product of its pipeline candidates into the clinic.”

VDMN is intended to locally stimulate the immune system resulting in immune system recognition and clearance of the virus that causes common warts – the human papillomavirus (HPV). VDMN is applied immediately adjacent to the wart and left in place for five minutes prior to removal. During this time, the dissolvable microarray releases the immunotherapy-based active ingredient into the epidermis and superficial dermis. In this dose-ranging Phase 2 study, qualified individuals will receive therapy every three weeks for up to six treatments.

“We are very excited to announce the first patient dosed with VDMN, our flagship product candidate,” said Tim Durso, MD, President at Veradermics. “Treatments for common warts are a critical unmet need in dermatology, for which there has been limited advancements for decades. We are optimistic about the potential for VDMN to bring much-needed change to the common wart treatment landscape and look forward to conducting this study.”

About Common Warts:

Common warts are a viral skin infection caused by HPV. Common warts affect ~19 million Americans and result in approximately 2.2 million visits with a healthcare provider annually in the U.S. alone. Common warts may persist for years without treatment. Currently, there are no FDA-approved prescription treatments for this condition.

About Veradermics:

Veradermics Inc. is a medical dermatology company driven to develop innovative therapeutics aimed at transforming the standard of care for a wide range of common skin conditions. Founded by dermatologists, Veradermics leverages its front-line clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. The company has cultivated a pipeline of diverse, first-in-class therapeutics for highly prevalent dermatologic conditions seen in adults and children. Target indications include common warts, alopecia areata, molluscum contagiosum, androgenetic alopecia (pattern hair loss), and atopic dermatitis. Veradermics is led by an executive team of board-certified dermatologists supported by a board of directors comprised of recognized biopharmaceutical industry leaders. For more information, visit http://www.veradermics.com.

Forward-Looking Statements:

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe”, “may” and “will” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Veradermic’s management about VDMN as treatment for patients with skin disease. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. The forward-looking statements are made as of this date and Veradermics does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Share article on social media or email:

Benchmark at Hanover Executive Director Receives Annual “President’s Award”


Fatima Feliciano, executive director, Benchmark at Hanover

“I am so grateful for the work that Fatima and all of our associates do every single day to transform lives through human connection.” -Tom Grape, founder, chairman and CEO

Benchmark, the largest senior housing provider in New England, today announced that Fatima Feliciano, CDAL, of East Bridgewater, Mass., executive director of Benchmark at Hanover, an assisted living and Mind & Memory Care community, has received the Benchmark 2023 President’s Award, which is the Waltham-based company’s highest honor for associates in a senior leadership role.

At the company’s 20th Annual Awards Gala held on March 9, 2023, Feliciano was selected for exhibiting outstanding operational leadership in opening Benchmark at Hanover, the company’s latest development, which opened in October 2022.

It’s her direction that has created an environment in which Benchmark at Hanover’s strong team of associates are wholly committed to the company’s high standards and making its residents feel at home. Residents and their families expressed high satisfaction for the community because of Feliciano’s stewardship.

One family member wrote, “The entire team evokes an atmosphere of dignified and quality care for all the residents. Our observation is of a community of residents that have become neighbors and friends. We are happy to find such a great living alternative for our brother.”

Feliciano initially joined Benchmark in 2018 as the executive director of Benchmark Senior Living at Plymouth Crossings before being selected in 2021 to open Benchmark at Hanover. Prior to Benchmark, Feliciano, a Certified Director of Assisted Living (CDAL), had a career in residential property management for more than a decade. It was a profession in which she excelled, but she felt something was missing, which is what brought her to Benchmark and assisted living.

“I am so grateful for the work that Fatima and all of our associates do every single day to transform lives through human connection,” says Tom Grape, founder, chairman and CEO of Benchmark. “Our annual awards gala is an opportunity for associates from across the Northeast to come together to celebrate our communities and colleagues who bring our purpose to life and live our values. This year’s award winners are truly exemplary, and I could not be prouder of all that we have accomplished together.”

# # #

About Benchmark Senior Living

Benchmark is New England’s largest senior living provider with 64 independent living, assisted living, memory care and continuing care communities and over 5,000 dedicated associates providing compassionate care and outstanding experiences throughout the Northeast. The Waltham, Mass.-based company was founded over 25 years ago by Tom Grape with the purpose of Transforming Lives Through Human Connection. Since then, Benchmark has continued to set the industry standard, having won over a hundred local, regional and national awards for its care, programs and as a top workplace. Benchmark has been named one of the Top Places to Work for 15 straight years in The Boston Globe’s annual employee-based survey and received repeated recognition in FORTUNE’s Best Workplaces for Aging Services list. For more information, visit BenchmarkSeniorLiving.com.

Share article on social media or email:

AltaPointe Health Receives Grant to Expand Law Enforcement Training for Mental Health to East Alabama


AltaPointe Health is an extensive mental health and family medical healthcare system in Alabama.

“The safe handling of a potential crisis is a win-win for everyone involved in the situation,” ADECA Director Kenneth Boswell said. “ADECA is pleased to join Gov. Ivey in supporting this beneficial training program.”

Earlier this month, Governor Kay Ivey awarded a grant to AltaPointe Health’s CCRT Mental Health Partnership to provide specialized training for law enforcement, correctional officers and first responders in Clay, Coosa, Randolph and Talladega counties.

The Collaborative Crisis Response Training provided by AltaPointe Health helps first responders correctly identify when a person’s behavior is a result of mental illness, substance use or other disorders. The training also involves techniques and intervention strategies for successfully diffusing and handling those situations.

“Our law enforcement officers and first responders place themselves in potential peril every time they respond to a call or pull over a vehicle,” Gov. Ivey said in a recent news release about the grant. “This training will be a very valuable resource in helping responders in these counties to determine what actions to take when facing these difficult and often unforeseen challenges.”

The Alabama Department of Economic and Community Affairs is administering the grant from funds made available by the U.S. Department of Justice.

“The safe handling of a potential crisis is a win-win for everyone involved in the situation,” ADECA Director Kenneth Boswell said. “ADECA is pleased to join Gov. Ivey in supporting this beneficial training program.”

PROVEN SUCCESS

AltaPointe’s CCRT Mental Health Partnership has already proven successful in south Alabama. The program started three years ago, and AltaPointe now trains more than 700 law enforcement officers in Mobile and Baldwin counties each year.

“We are proud of the dynamic and successful partnerships AltaPointe has developed with various law enforcement agencies over the last few years. Any opportunity to give our first responders the tools to handle mental health crises benefits the entire community,” explained Cindy Gipson, PhD, associate director for crisis services with AltaPointe Health.

During an August 2022 standoff in Mobile, the specialized training played an integral role in getting the individual psychiatric treatment instead of ending up in jail, and everyone involved walked away unharmed.

“It gave me a whole new perspective on the approaches and how we can actually mitigate some of the things that we see that are mental health related in our community,” said Mobile Police Commander Curtis Graves following the incident. “It also lessens the impact on our county jail. But more importantly, it keeps everyone safe, and keeps our officers safe.”

In addition to working with police officers and sheriff’s deputies, AltaPointe has also provided mental health crisis training to Alabama state troopers and 911 dispatchers.

ABOUT ALTAPOINTE

AltaPointe Health is an extensive mental health and family medical healthcare system in Alabama. Our clinicians provide more than 1.3 million hospital, outpatient, residential and crisis services annually.

Share article on social media or email:

DesignRush Launches “Spotlight Expert Contributors Program”


DesignRush launches an Expert Contributors Program for its media platform, Spotlight

Spotlight expert contributors can expand their reach to a B2B network of over 20,000 brands and agencies

DesignRush, a B2B Marketplace connecting businesses with agencies, launches the “Spotlight Expert Contributors Program” to expand its knowledge base of news, interviews and trends in the following industries:


  • Branding and creative
  • Web and app development
  • Marketing
  • Tech
  • Business services

Expert contributors can pitch topics and collaborate with the Spotlight team in creating valuable and engaging materials for the following audiences:


  • An average of 400,000 monthly visitors, primarily global B2B leaders and decision-makers
  • B2B network of over 20,000 brands and agencies
  • 45,000+ social media followers
  • 40,000+ newsletter subscribers
  • 200+ global media pick-ups

Check how to apply and find out if you are qualified to be an expert contributor here.

About DesignRush:

DesignRush.com is a B2B marketplace connecting businesses with agencies through expert reviews and agency ranking lists, awards, knowledge resources and personalized agency recommendations for vetted projects.

Share article on social media or email:

The Fight for Transparent Drug Pricing in America


News Image

The American people deserve to make informed choices with all cards face up. The Biden administration has made that impossible by putting the needs of Big Pharma before the needs of patients. FGA is fighting for transparency that puts people first. – Tarren Bragdon

Yesterday, the Foundation for Government Accountability (FGA) filed a federal lawsuit (Case 2:23-cv-00207) against the U.S. Departments of Health and Human Services (HHS), Labor, and Treasury for lack of enforcement of a drug price transparency rule which requires group health plans and health insurers to publish prescription drug prices to give consumers full pricing information for medications.

The Trump administration announced the Transparency in Coverage effort in 2019. The rule was finalized in 2020 and the drug price transparency provision was set to take effect on January 1, 2022. But before the rule could take effect, the Biden administration used an FAQ guidance document to block enforcement of the rule.

“Two years of inaction on drug price transparency is enough. FGA is taking the fight for transparency to federal court to force the Biden administration to follow the law, without exception and without delay,” said Tarren Bragdon, President and CEO of FGA. “Patients have a fundamental right to control their own health care decisions and that includes budgeting for medical expenses and prescriptions. Without full pricing information, families are left with higher costs and lower confidence in our health care system.”

“The American people deserve to make informed choices with all cards face up. The Biden administration has made that impossible by putting the needs of Big Pharma before the needs of patients,” added Tarren Bragdon. “FGA is fighting for transparency that puts people first.”

The Biden administration’s refusal to enforce this rule effectively repeals the price transparency consumers were excepting to help lower medical expenses. Instead, more than 1,200 prescription drugs saw their prices increase faster than inflation between 2021 and 2022.

“Refusing to enforce a rule on the books without following the formal process of withdrawing the rule is a violation of federal law. FGA is taking this fight directly to the federal court to order the implementation and enforcement of this drug price transparency rule,” said Stewart Whitson, FGA legal director. “There are no excuses left for the Biden administration: Either they are for transparency or against. Since they won’t implement the rule on their own as the law requires, we’re asking the federal court to order them to, delivering the transparency consumers deserve.”

###

The Foundation for Government Accountability (FGA) is a non-profit, multi-state think tank that promotes public policy solutions to create opportunities for every American to experience the American Dream. To learn more, visit TheFGA.org.

Share article on social media or email:

Missing Teeth? Clearwater Periodontist Offers High-Tech Solutions


Britten Periodontics & Implant Dentistry is a periodontal practice offering patients personalized dental care in implant dentistry in Clearwater, Florida. Dr. Todd Britten offers sedation dentistry.

“Dental implants provide an excellent long-term solution to replacing a single missing tooth or multiple missing teeth.” Dental implants have the highest success rate of all tooth replacement options designs and can be designed to be a perfect match for a natural-looking, lifelong smile.

Are you missing teeth? Clearwater Periodontist Dr. Todd Britten explains that 60% of adults aged 35-44 have lost one or more of their permanent teeth!

“Dental implants provide an excellent long-term solution to replacing a single missing tooth or multiple missing teeth,” Says Dr. Todd Britten. He went on to explain dental implants have the highest success rate of all tooth replacement options and says his experienced team designs your dental implants to be a perfect match for a natural-looking, lifelong smile.

Benefits of dental implants include:

  • Strong, stable, function that is similar to a natural tooth
  • Dental implants are the gold standard of care for replacing missing teeth
  • Gets rid of the need to remove your teeth, slur your speech or limit food choices

Dr. Britten also explains that dental implants with dentures are now an option for many patients. Before dental implants, people were limited to wearing complete dentures that could be very unstable, unreliable and unsupported. With as few as two to four implants, our team can create a stable foundation so that your general dentist can fabricate a removable denture that snaps securely in place.

Benefits of Implant-Retained Dentures include:

  • Stronger fit: Prevent slippage and hold dentures securely in place
  • Stop bone loss: Prevent continued bone loss from denture use and help maintain your natural facial structure
  • Less pain: Eliminate painful sore spots caused by denture pressure points
  • Speak more clearly: Dentures are better secured allowing to naturally pronounce words

Britten Periodontics & Implant Dentistry is a periodontal practice offering patients personalized dental care in implant dentistry in Clearwater, Florida. Dr. Todd Britten offers sedation dentistry. For more information, visit https://www.brittenperio.com

Share article on social media or email:

Endometriosis Awareness featured on the Meg Ryan-hosted Empowered series


News Image

Each segment is developed using cutting-edge filming techniques and technologies to create quality, engaging content.

The educational program Empowered, hosted by Meg Ryan, will be developing a new episode covering endometriosis. The series will feature conversations with some of the forerunners of endometriosis research and treatment to bring awareness to the health condition.

Empowered was created to shed light on various topics spanning numerous industries that impact the lives of countless individuals every day.

Endometriosis affects an estimated 200 million women globally, with 1 in 10 women in the U.S. estimated to have the condition. Endometriosis is an inflammatory condition that causes endometrial tissues to grow on the outside of the uterus. Symptoms of the disorder include chronic pelvic or abdominal pain, painful menstruation, and pain during sexual intercourse. It can be physically debilitating for many women and can cause infertility.

March is Endometriosis Awareness Month. Leading researchers and advocates come together during this time to bring further awareness to the disease to advocate for those living with the condition, and encourage funding and training for endometriosis treatment.

Currently, the cause of endometriosis is unknown. Although many scientists believe genetics play a role in the disease. Treatments include immune modulators, hormonal therapy, anti-inflammatory drugs, alternative medicine, and surgery.

Content for the episode discussing endometriosis was provided by related organizations specializing in research and treatment of the disease. The influential Hollywood actress Meg Ryan will serve as the host for the episode.

Empowered with Meg Ryan is an informational program distributed across multiple networks. Each segment is developed using cutting-edge filming techniques and technologies to create quality, engaging content. A team of individuals with decades of combined experience use their expertise to produce meaningful content for the Empowered program.

Share article on social media or email: